March 8, 2026
Statin Therapy for Primary Prevention and Clinical Outcomes in Adults Aged 80 and Older: A Retrospective Comparative Cohort Study.
Key result
Primary prevention statins in adults 80+ linked to lower mortality and coronary morbidity.
- HR 0.69
- 95% CI 0.34-0.74
- P<0.001
- n=15,745
Why the study?
Does persistent statin therapy reduce mortality and coronary events in adults aged 80 and older without prior cardiovascular disease?
Population
Patients aged ≥ 80 years
Comparison
Statin therapy for primary prevention vs no statin therapy or discontinuation
Design
Retrospective comparative cohort study
Authors
Discussion
Loading...
Member takes
Implication
May support statin use for primary prevention in adults ≥80; extends evidence to this understudied population.
Key Points
- To assess the long-term clinical effectiveness and safety of statin therapy for primary cardiovascular disease prevention in individuals aged 80 years and older.
- Conducted a population-based retrospective cohort study of 15,745 patients aged ≥ 80 years (mean age 84.5 years; 66% female) without prior cardiovascular disease using electronic health records from Israel between 2015 and 2020.
- Compared persistent statin users (n = 8,413) to non-users, excluding individuals receiving dialysis or those who died within one year of baseline follow-up.
- Evaluated all-cause mortality, new coronary events, myopathy, dementia, and diabetes using adjusted Cox proportional hazards models over a mean 4-year follow-up.
- Statin use was associated with a 31% reduction in all-cause mortality (HR 0.69; 95% CI: 0.34-0.74; p < 0.001) and a 20% reduction in new coronary events (HR 0.80; 95% CI: 0.68-0.94; p = 0.008).
- No significant differences were identified between groups regarding the risk of adverse clinical outcomes, including myopathy, dementia, or diabetes mellitus.
- Clinical protective benefits were absent among patients who discontinued statin therapy prior to reaching age 80.
Study Design
Type
Cohort (n=15,745)
Structured PICO
Does persistent statin therapy reduce mortality and coronary events in adults aged 80 and older without prior cardiovascular disease?
P
Population
15,745 adults aged ≥ 80 years without prior cardiovascular disease, followed for a mean of 4 years to evaluate statin therapy for primary prevention.
E
Exposure
Persistent statin therapy
C
Comparator
Similar patients not receiving statins
O
Outcome
All-cause mortalityhard clinical
Main Result
Hazard Ratio: 0.69 (95% CI 0.34–0.74)
p-value: p=< 0.001
In adults aged 80 and older, persistent statin therapy for primary prevention is associated with significant reductions in all-cause mortality and new coronary events without increasing the risk of adverse events.
Cite This Study
Lavon et al. (2026) conducted a cohort in Primary prevention of cardiovascular disease (n=15,745). Statin therapy vs. Similar patients not receiving statins was evaluated on All-cause mortality (HR 0.69, 95% CI 0.34-0.74, p=< 0.001). In adults aged ≥ 80 years without prior cardiovascular disease, statin use was associated with a 31% reduction in all-cause mortality (HR 0.69; 95% CI 0.34-0.74; p<0.001).